Skip to Content

Fisher & Paykel Healthcare Corp Ltd

FPH: XASX (AUS)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
A$27.00GtcwjgPrvkfydhh

Fisher & Paykel Reports In-Line Full-Year Result

We still see the risk-reward proposition as skewed to the downside for Fisher & Paykel, with shares trading at a 20% premium to our unchanged NZD 11.00 (AUD 10.00) fair value estimate. Fisher & Paykel's fiscal 2018 net profit after tax, or NPAT, of NZD 190 million was broadly in line with our NZD 188 million estimate. The 4% miss on the revenue line was largely offset by solid EBIT margin improvement to 27.5% for the year, up from 26.8% a year ago and beating our 26.3% forecast, aided further by a lower-than-expected net interest charge.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of FPH so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center